NXY-059

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cerebral Stroke

Conditions

Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke, Ischemic Attack, Transient

Trial Timeline

May 1, 2003 → Sep 1, 2006

NCT ID

NCT00061022

About NXY-059

NXY-059 is a phase 3 stage product being developed by AstraZeneca for Cerebral Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT00061022. Target conditions include Cerebral Stroke, Stroke, Acute, Cerebrovascular Stroke.

What happened to similar drugs?

5 of 16 similar drugs in Cerebral Stroke were approved

Approved (5) Terminated (1) Active (11)

✅mouse nerve growth factorSun PharmaceuticalApproved

✅RosuvastatinAstraZenecaApproved

✅clopidogrel (SR25990C)SanofiApproved

✅PiracetamUCBApproved

✅Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.Brain BiotechApproved

🔄Oral Glycopyrrolate LiquidShionogiPhase 3

🔄NXY-059AstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00075959	Phase 2	Completed	Aug 1, 2004	Jan 1, 2006	Intracerebral Hemorrhage
NCT00119626	Phase 3	Completed	Jun 1, 2003	Feb 1, 2005	Cerebral Stroke
NCT00061022	Phase 3	Completed	May 1, 2003	Sep 1, 2006	Cerebral Stroke

Competing Products

20 competing products in Cerebral Stroke

See all competitors

Product	Company	Stage	Hype Score
mouse nerve growth factor	Sun Pharmaceutical	Approved	39
Edaravone Dexborneol + Placebo	Sun Pharmaceutical	Phase 2	31
Oral Glycopyrrolate Liquid	Shionogi	Phase 3	40
recombinant human erythropoietin alfa + 0.9% NaCl	Johnson & Johnson	Phase 2/3	38
UDI-001	Rohto Pharmaceutical	Phase 1/2	32
NXY-059	AstraZeneca	Phase 2	35
Rosuvastatin	AstraZeneca	Approved	39
NXY-059	AstraZeneca	Phase 3	40
Comparator: Placebo + Comparator: MK0724	Merck	Phase 2	27
Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg	Merck	Phase 2	35
Recombinant Factor VIIa + Biological/Vaccine: Placebo	Novo Nordisk	Phase 3	47
Recombinant Activated Factor VII (rFVIIa) + Placebo	Novo Nordisk	Phase 3	44
Ponezumab	Pfizer	Phase 2	35
PF-05230907	Pfizer	Phase 1	21
Azithromycin + Pyrimethamine + Leucovorin calcium	Pfizer	Phase 1	29
clopidogrel (SR25990C)	Sanofi	Approved	43
Intrarectal quinine	Sanofi	Phase 3	36
Piracetam	UCB	Approved	35
Placebo + ALN-APP	Alnylam Pharmaceuticals	Phase 2	39
CN-105	Tiantan Bio	Phase 2	28